Joseph Thome
Stock Analyst at TD Cowen
(0.84)
# 3,683
Out of 4,735 analysts
24
Total ratings
42.11%
Success rate
-10.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $18.41 | - | 1 | Nov 25, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Hold | n/a | $0.54 | - | 2 | Oct 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $367.97 | +8.70% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $13.27 | - | 1 | Jul 2, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | n/a | $2.55 | - | 2 | Jun 18, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $30.10 | +12.96% | 1 | Jun 17, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $90 | $126.50 | -28.85% | 2 | Apr 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $2.91 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $2.72 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $45.25 | -33.70% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.19 | - | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $38.98 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.65 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.00 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $96.18 | +35.16% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.94 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.06 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.11 | - | 1 | Jul 15, 2021 |
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $18.41
Upside: -
Marinus Pharmaceuticals
Oct 25, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.54
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $367.97
Upside: +8.70%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $13.27
Upside: -
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.55
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $30.10
Upside: +12.96%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $80 → $90
Current: $126.50
Upside: -28.85%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $2.91
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.72
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $45.25
Upside: -33.70%
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.19
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $38.98
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $5.65
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $6.00
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $96.18
Upside: +35.16%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $9.94
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.06
Upside: -
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.11
Upside: -